Category: Hormone Health

Testosterone, estrogen, thyroid, growth hormone and the evidence behind hormone therapy in men and women.

  • Testosterone, the Black Sheep of Medicine

    Testosterone, the Black Sheep of Medicine

    Why primary care hesitates, and why the story is less about one hormone than about sport, scandal, a decade-long heart scare, and clinics that made saying yes look like the problem.

    Medical glass vials and a sterile syringe on a white background.
    Medical glass vials and a sterile syringe on a white background.

    The short version

    • Testosterone is the only common replacement hormone that is also a Schedule III controlled substance and a banned doping drug. Thyroid hormone, insulin and estrogen are not controlled substances. Estrogen is expressly excluded from the anabolic-steroid definition in US law.
    • A 2013 to 2014 cardiovascular scare drove prescribing down 48% in established users and 62% in new users between 2013 and 2016, on the strength of observational studies and a meta-analysis, not a randomized safety trial.
    • TRAVERSE (2023, n=5,246) found testosterone gel noninferior to placebo for major cardiovascular events (7.0% vs 7.3%; HR 0.96). In February 2025 the FDA removed the boxed warning on cardiovascular risk, and added a blood-pressure warning at the same time.
    • The guidelines never banned testosterone. They require symptoms plus two low early-morning levels, a search for the cause, and monitoring. Much of the reluctance is about everything around the prescription, not the molecule alone.

    The drug with three identities

    Ask a primary care doctor to replace thyroid hormone and nobody blinks. Levothyroxine is deficiency medicine: measure, replace, recheck. Insulin is the same. Estrogen, for all its own controversies, is prescribed as hormone therapy. Testosterone should sit in that same row, a hormone, replaced when it is genuinely low, monitored like any other.

    It does not sit in that row. Testosterone is the only common replacement hormone that carries three identities at once: medicine, crime, and cheating. It is a legitimate treatment for hypogonadism. It is also a Schedule III controlled substance under the US Controlled Substances Act, regulated by the DEA in the same tier as ketamine and codeine combination products, a category defined by accepted medical use alongside potential for abuse. And it is the archetypal doping drug, the substance behind stripped medals and fallen champions.

    That triple identity is not rhetoric. It is written into the statute itself. Federal law defines an anabolic steroid as any drug or hormonal substance “chemically and pharmacologically related to testosterone (other than estrogens, progestins, and corticosteroids) that promotes muscle growth” (21 U.S.C. §802). The definition is built around testosterone, and estrogen is carved out of it by name. Thyroid hormone and insulin were never in it at all.

    So a clinician who prescribes testosterone is, in regulatory terms, prescribing a drug of abuse, from a DEA-registered practice, for a documented legitimate medical purpose, on a prescription that expires in six months. Possession without a prescription is a federal crime. No other hormone on the shelf asks the prescriber to work inside that frame. Clinicians absorbed the framing along with the pharmacology: this is the hormone you defend, not the hormone you simply replace.

    Every other replacement hormone is treated as deficiency medicine. Testosterone alone arrives at the visit with a criminal record and a doping scandal attached.

    One honest limit before going further: no study found in the research for this article directly measured how much of today’s reluctance the legal history caused. The link is inferential. The law made the drug symbolically different, and practice culture followed. What is documented is the law, the scare that followed, and the measurable collapse in prescribing when that scare peaked. Those come next.

    How sport made a hormone a controlled substance

    Synthetic testosterone was isolated and synthesized in 1935 and used medically for decades, for hypogonadism, delayed puberty, some anaemias and some breast cancers, long before anyone scheduled it. The drug predates its criminalization by 55 years. What changed was not the medicine. What changed was sport.

    1935

    A medicine first

    Testosterone is isolated and synthesized. For the next five decades it is a prescription medicine for defined deficiencies, not a federally controlled substance.

    1988

    Seoul, and the scandal era

    Ben Johnson is stripped of Olympic gold at the 1988 Seoul Games after testing positive for a steroid. Congressional hearings follow in 1988 to 1990. The stated objective of the legislation that follows is to remove steroids from competitive sport and from cosmetic and bodybuilding use, not to regulate endocrinology.

    1990

    Anabolic Steroids Control Act of 1990

    Enacted 29 November 1990 as part of the Crime Control Act (Pub. L. 101 to 647), effective 27 February 1991. Anabolic steroids, originally 27 compounds, defined around testosterone, are placed in Schedule III. Non-medical use and distribution are criminalized.

    2004

    The net widens

    After the BALCO scandal, the Anabolic Steroid Control Act of 2004 (signed 22 October 2004, effective 20 January 2005) broadens the definition to capture designer steroids and prohormone precursors such as androstenedione sold as supplements. Sources disagree on the expanded list’s exact count, 49 versus 59 named substances, so no precise count is claimed here.

    2014

    Designer Anabolic Steroid Control Act

    About two dozen further designer steroids are added, with new offences for false labeling. The framework built for sport now fully surrounds a hormone doctors had prescribed since the 1930s.

    There is a contested footnote worth flagging rather than repeating as fact. Multiple secondary histories report that the AMA, FDA, DEA, NIDA and NIH testified against scheduling in 1988 to 1990, arguing anabolic steroids did not meet the Controlled Substances Act’s dependence criterion, and that Congress proceeded anyway to “send a message.” That account appears in secondary and partisan sources; it was not verified against a primary hearing record in the research for this article, so treat it as a widely repeated claim, not an established one.

    What needs no caveat is the direction of travel. A hormone became a controlled substance because of what athletes and bodybuilders did with it. Every prescriber since has inherited that decision, including the ones seeing a 58-year-old with two low morning levels and a textbook symptom picture, who has never been near a podium or a stage.

    The cardiovascular scare, 2013 to 2015

    If the law gave testosterone its reputation, the years 2013 to 2015 gave primary care its reason. Three publications, none of them a randomized safety trial, raised the possibility that testosterone therapy increased heart attacks, strokes and death. The FDA responded, labels changed, and prescribing fell off a cliff.

    On 31 January 2014, the FDA issued a Drug Safety Communication announcing it was evaluating the risk of stroke, heart attack and death with approved testosterone products. That September, an FDA advisory committee voted 20 to 1 to restrict the indicated population and require a cardiovascular safety trial. On 3 March 2015, the FDA required label changes: testosterone was approved only for men with low testosterone caused by certain medical conditions; benefit and safety for low testosterone due to aging were not established; and labels had to carry information about a possible increased risk of heart attack and stroke. The FDA’s own wording was careful, “possible” with some studies showing risk and others not. In practice, careful wording rarely survives contact with a busy clinic. What survived was the warning.

    Observational · VA cohort

    Vigen et al., JAMA 2013

    Design: Retrospective national VA cohort of 8,709 men with total testosterone <300 ng/dL who had coronary angiography (2005 to 2011); 1,223 started testosterone.

    Finding: Composite of death, MI and ischaemic stroke at 3 years: 25.7% (testosterone) vs 19.9% (no testosterone) on Kaplan, Meier estimates; adjusted HR 1.29 (95% CI 1.04 to 1.58).

    Limit: Retrospective and not randomized. Who gets treated, and why, cannot be separated from the result. Critics noted the raw event count was lower in the treated group (123/1,223, 10.1% vs 1,587/7,486, 21.2%) and that the headline figures were model-based estimates; JAMA issued corrections. The claim that the study is therefore “reversed” is itself contested.

    Observational · Claims data

    Finkle et al., PLoS One 2014

    Design: Claims-database cohort of 55,593 men with a first testosterone prescription, comparing non-fatal MI in the 90 days after the prescription with the prior year.

    Finding: Post/pre rate ratio 1.36 (95% CI 1.03 to 1.81). In men ≥65, RR 2.19; in men <65, excess risk appeared only with prior heart disease (RR 2.90).

    Limit: The paper itself lists them: no data on indication, labs, race or lifestyle; no data on how much drug was actually taken; non-fatal MI only. In absolute terms the increase was small, about 1 additional MI per 1,000 person-years (3.48 to 4.75) in secondary analyses.

    Meta-analysis · 27 RCTs

    Xu et al., BMC Medicine 2013

    Design: 27 placebo-controlled trials, 2,994 mainly older men, 180 cardiovascular-related events in total.

    Finding: Pooled OR 1.54 (95% CI 1.09 to 2.18) for cardiovascular events, but the effect split sharply by funding: non-industry trials OR 2.06 vs industry-funded trials OR 0.89 (p for interaction 0.03).

    Limit: No included trial was designed to measure cardiovascular events; events were harvested from adverse-event reports with inconsistent definitions. A contemporaneous meta-analysis by Corona et al. (75 studies) found no cardiovascular risk (OR 1.07).

    A small 2010 randomized trial in frail older men (Basaria et al., the TOM trial) had also been stopped early for excess cardiovascular events, and it formed part of the background signal, though it was not one of the three studies the FDA action rested on.

    What the warning did to prescribing

    Baillargeon and colleagues tracked nearly 10 million commercially insured men in JAMA (2018). Testosterone use had climbed from 0.52% in 2002 to 3.20% in 2013, then fell to 1.67% by 2016. The relative decrease from 2013 to 2016 was 48% in established users and 62% in new users. The authors’ own words: “The steepest decrease coincided with 2 published reports of testosterone-associated adverse cardiovascular events and an FDA communication.” A VA study over the same period found a 40% decrease.

    Testosterone use among commercially insured US men ≥30, 2002 to 2016

    All users: 0.52% (2002) → 3.20% (2013) → 1.67% (2016). Source: Baillargeon et al., JAMA 2018;320:200 to 202, Clinformatics Data Mart, 9,962,538 men. Commercially insured (employed) men, not generalisable to retired or Medicare populations. Testosterone use had also tripled from 2001 to 2011, mostly in men without a clear indication, so part of the fall was likely correction of overprescribing, not just undertreatment.

    That last point matters, and honest writing about this topic has to hold both halves of it. Some of the prescribing that disappeared after 2013 should never have happened, the pre-2013 boom was driven substantially by men without a clear indication, in the era of “low T” advertising. And some of the men who lost access, or never got assessed, had the real disease. A blunt warning cannot tell those two groups apart. Clinicians, understandably, resolved the ambiguity by saying no more often, to everyone.

    What TRAVERSE actually showed

    The trial the FDA committee asked for in 2014 arrived in 2023. TRAVERSE (Lincoff et al., New England Journal of Medicine 2023) was the first adequately powered randomized cardiovascular safety trial of testosterone: 5,246 men aged 45 to 80, at 316 US sites, each with symptoms of hypogonadism, two fasting testosterone levels below 300 ng/dL, and either established cardiovascular disease or high cardiovascular risk. Men were randomized to daily 1.62% testosterone gel, dose adjusted to keep levels at 350 to 750 ng/dL, or matching placebo. Mean treatment duration was 21.7 months; mean follow-up was 33.0 months.

    TRAVERSE: the primary result

    5,246
    Men randomized, 45 to 80 years, confirmed low testosterone + symptoms + high CV risk
    7.0% vs 7.3%
    Major adverse cardiovascular events (CV death, nonfatal MI, nonfatal stroke): testosterone vs placebo
    HR 0.96
    95% CI 0.78 to 1.17 · P<0.001 for noninferiority, upper limit well below the 1.50 margin
    33.0 mo
    Mean follow-up (mean treatment duration 21.7 months), gel only, physiological target range

    In plain terms: in this population, at physiological doses, testosterone did not increase major cardiovascular events versus placebo. Noninferiority is not superiority. TRAVERSE did not show testosterone prevents events.

    What it showed

    • No increase in the primary MACE composite over ~3 years of follow-up in men with confirmed hypogonadism and high cardiovascular risk.
    • Similar results in sensitivity analyses censoring at treatment discontinuation, and for the secondary composite including coronary revascularization.
    • Enough reassurance that on 28 February 2025 the FDA removed the boxed-warning language on increased cardiovascular risk from all testosterone labels and added the TRAVERSE results to them.

    What it did not show

    • Secondary signals: higher incidence on testosterone of atrial fibrillation, acute kidney injury and pulmonary embolism (stated in the abstract without numbers; precise percentages circulating in secondary summaries were not verified against the NEJM full text for this article).
    • Long-term safety beyond ~3 years; safety of injections (gel only); safety at supraphysiological, bodybuilding doses; safety in men without confirmed hypogonadism.
    • Efficacy for energy, vitality or cognition. It was a safety trial, not an efficacy trial for those outcomes. Prostate-cancer numbers were too few to prove equivalence.

    The limitations are real, too

    A widely cited critique in JACC Advances (2023), an opinion piece, and worth reading as one, makes points any honest summary should carry: about 61% of participants discontinued their gel or placebo, so much of the follow-up happened off treatment, diluting any true difference in an intention-to-treat analysis; roughly 18% were lost to follow-up; achieved testosterone levels hovered near the bottom of the 350 to 750 ng/dL target (men started at a mean of 227 ng/dL and rose only ~148 ng/dL at 12 months); the trial enrolled 5,246 of a planned ~6,000 men; it was funded by AbbVie and other manufacturers; and men with recent MI or stroke or uncontrolled heart failure, the highest-risk subgroup, were excluded.

    The accurate framing, then, is not “case closed.” It is: the best randomized evidence available excludes a large increase in major cardiovascular events over about three years, at physiological doses, in confirmed hypogonadism, and leaves the secondary signals open.

    And note what the FDA did not do in February 2025. It retained the limitation of use for age-related hypogonadism. It added a blood-pressure warning, after ambulatory monitoring studies confirmed a class-wide rise in blood pressure. Testosterone remains Schedule III. The label change is not a recommendation to prescribe, nor a declaration of safety for everyone. One specific warning came off; another went on. (Reports in 2026 secondary sources that HHS/FDA has requested further changes, removing the age-related limitation and narrowing the prostate contraindication, describe a request, not a completed change, and were not verified on an FDA primary page for this article.)

    Why primary care still hesitates

    If the heart question has been substantially answered, why does the hesitation persist? Because the cardiovascular scare was only ever one layer of it. Several real frictions stack up at once. Some are documented. Some are not. It helps to keep the two apart.

    ⚠ An honesty note on the evidence for this section

    No quantitative US survey of primary-care physicians’ attitudes toward testosterone prescribing was found in the research for this article. Reasons such as “minimal hormone training in residency” “fear of litigation or board action” and “prior-authorization burden” appear repeatedly in clinic and trade commentary, but no curriculum study, malpractice dataset or payer-policy source was found to verify them. They are presented below as commentary-level claims, plausible, widely repeated, and not survey-established fact.

    The one peer-reviewed attitudinal study found is British, qualitative and small: interviews with 20 men (aged 45 to 62), 30 GPs and 10 endocrinologists, published in the Journal of Men’s Health in 2024 and commissioned by Besins Healthcare UK. Its findings are recognisable on either side of the Atlantic. Many GPs were unaware of the full range of testosterone-deficiency symptoms and did not think to check testosterone for non-specific complaints like fatigue and low energy, which were attributed to aging or work stress. Many lacked confidence in managing the condition and wanted standardized, guideline-based care. Stigma, embarrassment and “machismo” inhibited men from raising symptoms at all, and limited consultation time blocked the longer conversation. Endocrinologists, for their part, believed many referred men could be managed appropriately in primary care. Small, qualitative and industry-funded, but it points to knowledge gaps, low confidence, stigma and time pressure, not to a single cause.

    The documented frictions

    Documented

    A diagnosis that takes work

    Guideline diagnosis requires symptoms plus two early-morning fasting measurements, then LH/FSH, PSA and haematocrit, then a search for the cause, depression, hypothyroidism, sleep apnoea, obesity, opioids and pituitary disease can all sit behind the same complaints. A single low number is not a diagnosis, and ruling the mimics out is real work in a short visit.

    Documented

    A monitoring burden that never ends

    Both major guidelines require baseline and ongoing monitoring of testosterone, haematocrit and prostate risk (details in the next section). That is a standing obligation, repeat labs, dose decisions, stop rules, attached to every prescription, indefinitely.

    Documented

    Fertility cuts the other way

    Exogenous testosterone suppresses LH and FSH and with them sperm production. Both guidelines advise against starting it in men planning fertility in the near term; the AUA states it should not be prescribed to men currently trying to conceive. In younger men, hesitation is often the guideline working as intended.

    Documented

    Controlled-substance gravity

    Schedule III status brings DEA registration, legitimate-medical-purpose documentation and diversion concern to every script. The regulatory facts are established; how heavily they weigh on individual clinicians’ decisions is inferred, not surveyed.

    Commentary-level

    Training, liability and paperwork

    Clinic commentary routinely cites minimal hormone training, fear of liability, prior-authorization fights and 15-minute visit economics. Each is plausible; none was verified against a primary source in this research. Treat them as the profession’s folklore until someone surveys it properly.

    Documented, indirectly

    Guilt by association

    A GP who prescribes testosterone risks being read as practicing “low-T clinic” medicine, because, as the next sections show, a visible part of that market prescribes without diagnosis, monitoring or thresholds. No survey quantifies the reputational effect, but the overprescribing it reacts to is documented.

    Stack those together and “no” becomes the path of least resistance: a safety scare that has been superseded but is still seared in, a genuinely demanding diagnostic and monitoring protocol, a controlled-substance framework, and a cultural association with doping and anti-aging marketing. Not because the doctor has read TRAVERSE and rejected it. Often because the doctor trained during the warning years, never built the monitoring workflow, and has a waiting room full of problems that come with fewer questions attached.

    What the guidelines actually say

    Here is the part that surprises patients most: the guidelines are not against testosterone. The Endocrine Society (Bhasin et al., 2018), the American Urological Association (Mulhall et al., 2018) and, most narrowly, the American College of Physicians (2020) all describe a legitimate treatment for a defined condition. What they are against is treating a marketing category. “Low T” as advertised, fatigue, low energy, weight gain and fading vitality in aging men with borderline or unmeasured levels, is not the diagnosis any of them recognizes.

    Endocrine Society: Bhasin et al., J Clin Endocrinol Metab 2018

    • Diagnose only in men with symptoms/signs consistent with testosterone deficiency and unequivocally, consistently low serum testosterone.
    • First test: fasting morning total testosterone with an accurate assay, then confirm by repeating it. Add free testosterone (equilibrium dialysis or accurate formula) when total T is near the lower limit or SHBG is altered. Then evaluate the cause.
    • Treat symptomatic deficiency after discussing benefits, risks and monitoring, shared decision-making, aiming for mid-normal concentrations.
    • Against routine screening of the general population, and against routinely prescribing to all men ≥65.
    • Do not start with: plans for near-term fertility; breast or prostate cancer; palpable prostate nodule; PSA >4 ng/mL (>3 if at increased risk) without urological evaluation; elevated haematocrit; untreated severe sleep apnoea; severe lower urinary tract symptoms; uncontrolled heart failure; MI or stroke within 6 months; thrombophilia.
    • Monitor: symptoms, adverse effects and compliance; serum testosterone and haematocrit; prostate-cancer risk during the first year.

    Full text detail beyond the published abstract (exact monitoring intervals, haematocrit thresholds) is widely summarized secondhand; figures not in the abstract were not treated as verified for this article.

    The diagnosis, step by step

    What a guideline-concordant work-up actually looks like, the standard a prescription should be measured against:

    1. Symptoms firstConsistent symptoms or signs of testosterone deficiency, not a number looking for a patient, and not fatigue alone without the rest of the picture.

    2. Two early-morning fasting levelsTotal testosterone measured on two separate occasions, both early morning and fasting, with a reliable assay, below the cut-off both times (AUA: <300 ng/dL as a reasonable threshold).

    3. Find the causeLH (and prolactin if LH is low), plus a search for reversible drivers, obesity, diabetes, opioids, sleep apnoea, pituitary disease, before replacing anything.

    4. Screen the contraindicationsFertility plans, prostate risk (PSA, examination), haematocrit, sleep apnoea, heart failure, recent MI or stroke, thrombophilia.

    5. Treat to mid-normal, and monitorShared decision-making, a mid-normal target (not an enhancement target), then scheduled testosterone, haematocrit and prostate monitoring, with a willingness to stop if symptoms do not improve.

    Where the caution is justified

    A piece arguing that testosterone is medicine’s black sheep would be dishonest if it pretended the wariness has no basis. Some of it is the correct clinical response to a drug with real effects beyond the one being treated.

    Erythrocytosis: the most consistent risk

    Testosterone thickens the blood. A systematic review commissioned for the Endocrine Society guideline found testosterone increased the risk of haematocrit above 54% (RR 8.14, 95% CI 1.87 to 35.40); in the T4DM trial of injected testosterone undecanoate, haematocrit >54% occurred in 22% on testosterone vs 1% on placebo. This is why haematocrit monitoring is not bureaucratic decoration. (Figures via secondary summary of Ponce et al., JCEM 2018.)

    Fertility suppression

    Exogenous testosterone suppresses LH and FSH, lowers intratesticular testosterone and reduces, sometimes abolishes, sperm production. Recovery takes months to years and is not guaranteed. Prescribing it to a man who wants children, without that conversation, is a harm, full stop.

    Prostate: monitoring, not panic

    Neither guideline finds definitive evidence that testosterone causes prostate cancer, and TRAVERSE found no difference, with too few cancers to prove equivalence. But PSA rises slightly more on treatment, and active prostate cancer remains a contraindication. Monitoring is mandatory precisely because the question is managed, not settled.

    Sleep apnoea & blood pressure

    Untreated severe obstructive sleep apnoea is a guideline contraindication to starting, because testosterone can worsen it. And the FDA’s February 2025 action added a blood-pressure warning on ambulatory-monitoring evidence even as it removed the cardiovascular boxed warning. “The warning came off” is only half of that headline.

    And the low-T clinic problem is real

    The strongest evidence that some caution is warranted comes from the sellers, not the sceptics. In a secret-shopper study published in JAMA Internal Medicine (Dubin et al., 2022), researchers presented to seven direct-to-consumer testosterone platforms as a 34-year-old man with normal testosterone who wanted children. Six of the seven offered him testosterone anyway. Only one of seven asked about recent cardiovascular events or desire for fertility; six of seven had no testosterone threshold at all; half quoted a treatment target above 1,000 ng/dL, roughly double the mid-normal aim the guidelines describe.

    The pattern repeats at scale. A 2026 global analysis of 253 websites offering testosterone prescriptions found 9.9% prescribed for men with normal testosterone, 20.6% claimed testosterone reduces cardiovascular risk, and 9.9% marketed anti-aging effects, with US clinics the worst performers. And a single-center chart review presented at ENDO 2026, conference data, not yet peer reviewed, so weigh it accordingly, found that of 200 men prescribed testosterone between 2020 and 2025, only 12% had received a guideline-concordant evaluation: two low morning levels, LH/FSH, and no contraindications. A quarter of the prescriptions followed a patient request.

    That is the environment a primary care doctor is looking at when a patient arrives asking for testosterone by name. The refusal is sometimes aimed at the man in the room. Often it is aimed at the market behind him.

    The line worth holding

    Strip the history away and the evidence supports a clear, narrow position. Treating symptomatic, confirmed hypogonadism, two low morning levels plus symptoms, cause investigated, no contraindications, to mid-normal levels, with monitoring, carries the reassurance of a 5,246-man randomized trial on major cardiovascular events over about three years. The evidence does not support testosterone for energy, vitality or cognition alone; at supraphysiological targets; without baseline labs; in men with normal levels who want children; or as a substitute for asking why the level is low in the first place.

    The strongest version of the doctor’s case

    “I am not against testosterone. I am against this testosterone, prescribed without a diagnosis, without monitoring, at enhancement doses, by a clinic that profits from saying yes.”

    The strongest version of the patient’s case

    “I do meet the guideline criteria, and I am being refused on the basis of a 2013 scare that a 5,246-man randomized trial and a 2025 FDA label change have superseded.”

    Both of those people are right about the case they are describing. The failure happens when they are describing different cases and talking past each other, when a blanket “we don’t do testosterone here” meets a man who has done everything the guidelines ask, or when a legitimate prescription is expected to behave like the enhancement protocol a clinic advertised on a podcast.

    Testosterone earned its black-sheep status honestly, in stadiums and in strip-mall clinics, long before it reached the exam room. But a hormone is not its worst users. The drug synthesized in 1935 for men whose bodies could not make enough of it is still that drug. The task for primary care is not to rehabilitate its reputation or to keep punishing it, it is the duller, harder work the guidelines already describe: measure twice, find the cause, treat the deficiency, monitor the man. Do that, and testosterone stops being the black sheep. It becomes what thyroid hormone got to be all along, just another hormone, replaced properly.

    Open questions this article will not pretend are closed

    • No quantitative US survey of primary-care attitudes toward testosterone was found. The training, liability and prior-authorization explanations remain commentary level until one exists.
    • TRAVERSE’s secondary signals (atrial fibrillation, acute kidney injury, pulmonary embolism) are stated without numbers in the trial abstract; precise percentages in circulation come from secondary summaries.
    • Whether the reported 2026 request to remove the age-related limitation of use becomes a completed FDA label change is unresolved, as of the sources checked, it is a request, not a change.
    • Long-term safety beyond ~3 years, injectable formulations, and men at the very highest cardiovascular risk remain outside what TRAVERSE tested.
    Educational only. This article is general information about the evidence and history of testosterone therapy. It is not medical advice and does not establish a doctor-patient relationship. Testosterone is a Schedule III controlled substance available only by prescription after an individual evaluation. If you think you may have testosterone deficiency, the guideline-concordant next step is a conversation with your own clinician and two early-morning fasting measurements, not a single test, and not a direct-to-consumer platform that skips them.

    Follow @dr.francisco_md for the Saturday hormone-health series: protein after 40, peptides, estrogen in men, visceral fat and alcohol are next in the queue.

    References

    1. FDA. FDA issues class-wide labeling changes for testosterone products (28 Feb 2025), TRAVERSE results added; cardiovascular boxed warning removed; age-related limitation retained; blood-pressure warning added. fda.gov
    2. FDA Drug Safety Communication (3 Mar 2015): label changes, approved uses clarified; possible increased risk of heart attack and stroke. drugs.com
    3. Lincoff AM, et al. Cardiovascular safety of testosterone-replacement therapy (TRAVERSE). N Engl J Med. 2023;389(2):107 to 117. doi:10.1056/NEJMoa2215025. PubMed 37326322
    4. Bhasin S, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103(5):1715 to 1744. PubMed 29562364
    5. Mulhall JP, et al. Evaluation and management of testosterone deficiency: AUA guideline. J Urol. 2018;200(2):423 to 432. PubMed 29601923
    6. Qaseem A, et al. Testosterone treatment in adult men with age-related low testosterone: ACP clinical guideline. Ann Intern Med. 2020. acponline.org
    7. Vigen R, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA. 2013;310(17):1829 to 1836. PubMed 24193080
    8. Finkle WD, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. PLoS One. 2014;9(1):e85805. PMC3905977
    9. Xu L, et al. Testosterone therapy and cardiovascular events among men: systematic review and meta-analysis. BMC Med. 2013;11:108. PMC3648456
    10. Baillargeon J, et al. Testosterone prescribing in the United States, 2002 to 2016. JAMA. 2018;320:200 to 202. jamanetwork.com
    11. Dubin JM, et al. Guideline-discordant care among direct-to-consumer testosterone therapy platforms. JAMA Intern Med. 2022;182(12):1321 to 1323. medicalxpress.com summary
    12. Testosterone Replacement: Is it the TRAVERSE Trial or a Travesty? JACC Advances. 2023;2(10):100742. PMC11198716
    13. Barriers to diagnosis and accessing effective treatment and support for testosterone deficiency. J Men’s Health. 2024. doi:10.22514/jomh.2024.001. pharmacymagazine.co.uk summary
    14. Anabolic Steroids Control Act of 1990, Schedule III placement; statutory definition at 21 U.S.C. §802. en.wikipedia.org; DEA Schedule III status summary: legalclarity.org
    15. Global analysis of websites offering testosterone prescriptions. J Clin Endocrinol Metab. 2026;111(6):1651. academic.oup.com
    16. Testosterone prescribing often ignores guidelines, single-centre review presented at ENDO 2026 (conference report, not peer-reviewed). medscape.com

    Research verified 15 November 2026. Where a figure rests on a secondary summary rather than a primary text, the article says so at the point of use.

  • “Sports TRT” Is a Steroid Cycle With Better Marketing

    “Sports TRT” Is a Steroid Cycle With Better Marketing

    The pitch is that a prescription and a clinic visit turn a performance dose of testosterone into medicine. They do not. The category is defined by the dose and the indication, not by who signed for it.

    The pitch arrives with a medical vocabulary. Not a cycle, a protocol. Not steroids, optimization. Not a dealer, a men’s clinic. The dose is higher than replacement, the goal is performance and physique, and the thing that is supposed to make it different from what a bodybuilder does in a garage is that a licensed provider wrote for it.

    I spent four years competing in Men’s Physique and earned my IFBB Pro card in 2017. I also prescribe testosterone every week as an internist. From both chairs, the honest description of “sports TRT” is this: it is a steroid cycle, run at a steadier dose, with a prescription attached. The prescription changes the legal exposure and the quality of the vial. It does not change the pharmacology.

    The verdict in one paragraph

    Replacement therapy and performance dosing are separated by the serum level you are aiming for, not by the setting. Guidelines define testosterone replacement as treating a diagnosed deficiency and targeting the middle of the normal range, roughly 450 to 600 ng/dL, using the lowest dose that gets there. Doses chosen to exceed that range are, by the Endocrine Society’s own definition in its scientific statement on performance-enhancing drugs, supraphysiologic androgen use. The health consequences that follow, erythrocytosis, suppressed fertility, cardiac remodeling, and a hypothalamic-pituitary axis that may not recover, are dose-dependent and do not care what the regimen is called.

    The claimVerdictWhy
    “It’s TRT because a doctor prescribed it”FalseGuidelines define the therapy by diagnosis and target range, not by prescriber. A supraphysiologic dose is supraphysiologic on a prescription pad
    “Pharmaceutical-grade product makes it safe”FalseSterility and accurate concentration are real advantages over underground product. They do not change the dose-dependent effects on hematocrit, fertility or the heart
    “Monitoring makes the risk manageable”Partly trueMonitoring catches erythrocytosis and allows dose reduction. It does not prevent testicular suppression, and no monitoring protocol has been shown to prevent the cardiac findings seen in long-term users
    “TRAVERSE proved testosterone is cardiac-safe”OverstatedTRAVERSE tested replacement dosing, titrated to 350 to 750 ng/dL, in men with confirmed deficiency. It says nothing about performance doses in men with normal baseline levels
    “Steady weekly dosing is safer than a classic cycle”Plausible, unprovenAvoiding the crash of an on-off cycle is a reasonable hypothesis. No trial has compared continuous supraphysiologic dosing against cycled dosing on hard outcomes
    “It’s a steroid cycle”True, when the dose exceeds replacementSupraphysiologic androgen administration to a man who is not deficient is the textbook definition, whatever the label on the box

    What testosterone replacement is, as medicine defines it

    Three elements define the therapy, and all three have to be present.

    A diagnosis. The American Urological Association’s guideline uses a total testosterone below 300 ng/dL as the cutoff supporting a diagnosis, measured on two separate early-morning draws, and makes the clinical diagnosis only when those low levels sit alongside symptoms or signs. [Mulhall et al., 2018] Thresholds differ a little by society. The Endocrine Society uses 264 ng/dL, the AACE has used 200. [AUANews, 2023] No society defines deficiency by how a man feels at a normal level.

    A target. The AUA directs clinicians to aim for the middle third of the normal range, commonly cited as about 450 to 600 ng/dL, using the minimum dose that achieves it. The Endocrine Society’s phrasing is the mid-normal range. TRAVERSE, the FDA-mandated safety trial, titrated to 350 to 750 ng/dL. [Lincoff et al., 2023] Every one of those targets sits inside the physiologic range of a healthy man.

    A monitoring schedule. Symptoms, testosterone, and hematocrit at baseline, at three to six months, then annually, with therapy held if hematocrit exceeds 54%, plus PSA assessment in men over 40. [Bhasin et al., 2018]

    Notice what is absent from all of this: any provision for a man with a normal baseline who wants to be stronger. That is not an oversight. It is the boundary of the indication.

    What “sports TRT” actually is

    The term has no formal definition, which is part of its usefulness to the people selling it. In practice it describes one of two things.

    The first is a man with a genuinely normal baseline, often 400 to 600 ng/dL, who is prescribed testosterone anyway, typically 150 to 250 mg per week, with the stated goal of reaching 900 to 1,200 ng/dL or higher. The second is a man with a borderline level who is started at a dose far above what would be needed to correct it, and then titrated upward by symptoms that were never specific to testosterone in the first place.

    Both are the same thing pharmacologically. You are adding androgen to a man who does not lack it, to push him above his own physiology. The Endocrine Society’s 2014 scientific statement on performance-enhancing drugs describes exactly this population and is blunt about who it is: “the vast majority of PED users are not athletes but rather nonathlete weightlifters, and the adverse health effects of PED use are greatly underappreciated.” [Pope et al., 2014]

    The one real difference. I want to be fair about what the clinic actually provides. A prescription means a sterile, accurately dosed, pharmacy-sourced product instead of an underground lab vial of unknown concentration. It means bloodwork. It means someone notices when your hematocrit hits 56%. Those are not nothing, and harm reduction is a legitimate framework in medicine. But harm reduction is an argument for supervizing a risk, not a claim that the risk is gone, and it is not what is being advertised.

    Where replacement ends: the dose-response data

    We do not have to speculate about where the line sits. The question was answered directly by Bhasin’s dose-response work, which remains the cleanest human data we have on graded testosterone exposure.

    Healthy young men received a GnRH agonist to shut down their own production, then weekly testosterone enanthate at 25, 50, 125, 300, or 600 mg for 20 weeks. The resulting mean nadir testosterone concentrations were 253, 306, 542, 1,345, and 2,370 ng/dL respectively. [Bhasin et al., 2001]

    Read that series carefully, because it maps the entire argument.

    Weekly doseMean nadir testosteroneChange in fat-free mass over 20 weeksWhere this sits
    25 mg253 ng/dL−0.1 kgBelow the normal range
    50 mg306 ng/dL+1.1 kgLow-normal
    125 mg542 ng/dL+3.4 kgMid-normal: the replacement target
    300 mg1,345 ng/dL+5.2 kgRoughly double the top of normal
    600 mg2,370 ng/dL+7.9 kgFrank supraphysiologic exposure

    Fat-free mass changes from Bhasin et al., 2001; nadir concentrations measured one week after the preceding injection, so peak levels were higher still.

    Two things follow. The first is that about 125 mg per week lands a healthy man squarely in the middle of the normal range. That is what replacement looks like in a controlled setting. The companion trial in men aged 60 to 75 found the same thing and said so explicitly, concluding that the best trade-off between benefit and adverse effects was achieved at the 125 mg dose. [Bhasin et al., 2005]

    The second is that the muscle keeps coming above that line. Fat-free mass rose from +3.4 kg at 125 mg to +7.9 kg at 600 mg. This is the uncomfortable part, and pretending otherwise destroys your credibility with anyone who has spent time in a gym: more androgen does build more muscle. It just does so by leaving the range the human body is built to run in, and everything else on the dose-response curve rises with it.

    What the higher doses actually do

    Red cells thicken the blood, predictably and by dose

    Erythrocytosis is the most common dose-limiting effect of testosterone therapy. In the same dose-response cohorts, hemoglobin and hematocrit rose in a linear, dose-dependent fashion in both young and older men, and the effect was more pronounced with age. [Coviello et al., 2008] In the older cohort, several men had to be withdrawn for hematocrit above 54%; none of the young men crossed that threshold even at 600 mg weekly. [Bhasin et al., 2005] This is why 54% is the stop-and-reassess number in the guidelines, and it is the single most reliable consequence of pushing the dose up.

    Fertility: suppression is the expected result, not a rare complication

    The clearest data on this come from an unexpected source. The World Health Organization ran weekly 200 mg testosterone enanthate as a male contraceptive in a ten-center, seven-country trial of 271 healthy fertile men. By six months, 157 of them, a cumulative rate of 65%, had reached azoospermia on three consecutive semen samples, and the regimen was then used as the couples’ only form of contraception for twelve months. [WHO Task Force, Lancet 1990] The follow-up study across 15 centers found suppression to azoospermia or severe oligozoospermia in 97.8% of 399 men. [WHO Task Force, Fertil Steril 1996]

    When a dose is effective enough at shutting down sperm production to be studied as birth control, calling that effect a side effect understates it. Median time from azoospermia back to a sperm concentration of at least 20 million/mL after stopping was 3.7 months in the 1990 trial, which is reassuring, but those were healthy men on a defined protocol for a defined period, not men three years into continuous use.

    The same trial recorded gynecomastia in 24 of 271 men. [WHO Task Force, Fertil Steril 1996] Aromatization tracks total dose. More testosterone means more substrate.

    The heart: the finding that changed my own thinking

    Baggish and colleagues at Massachusetts General compared 86 long-term anabolic steroid users against 54 non-using weightlifters, all experienced lifters aged 34 to 54, using echocardiography and coronary CT angiography. Men who were on-drug at evaluation had meaningfully reduced left ventricular systolic function compared with non-users, with an ejection fraction of 49±10% versus 58±10%, along with reduced diastolic function. Users also carried greater coronary plaque volume than non-users, and, critically, lifetime cumulative dose was strongly associated with plaque burden. [Baggish et al., Circulation 2017]

    That last clause is the one that matters for this discussion. A dose-response relationship with coronary atherosclerosis is not a finding you can supervise your way out of. It is an argument about total exposure over years, which is precisely what continuous “sports TRT” delivers, arguably more faithfully than a cycled approach does.

    Imaging findings raise the question of whether events follow. A 2025 Danish registry study answered it by tracking cardiovascular diagnoses rather than scans, following men sanctioned for AAS use against age- and sex-matched controls over a mean of 11 years. The adjusted hazard ratios were not subtle: acute myocardial infarction 3.00 (95% CI 1.67 to 5.39), coronary intervention or bypass grafting 2.95, venous thromboembolism 2.42, and arrhythmia 2.26. [Windfeld-Mathiasen et al., Circulation 2025]

    These men had a mean age around 27 at entry. A threefold rate of myocardial infarction in a cohort that young is not a subtle population signal. The same caveats apply as to any registry study, and one specific limitation matters here: the investigators could not track whether individuals continued using after their sanction, so the exposure is “ever sanctioned” not a measured dose over time.

    Recovery is not guaranteed

    A Danish case-control study compared 37 current users, 33 former users who had been off for a median of about 2.5 years, and 30 healthy controls. Former users still had significantly lower total testosterone than controls, 14.4 nmol/L (about 415 ng/dL) versus 18.8 nmol/L (about 542 ng/dL), and 27.2% of former users were below the lower reference limit years after stopping. [Rasmussen et al., PLoS One 2016]

    Roughly one in four men who stopped had not gotten their own production back. This is the risk that is almost never priced into the decision at the front end, and it is the one that most often walks into my office: a man in his late thirties who started “optimization” at 32, stopped, and now needs genuine replacement for an iatrogenic deficiency he did not have before.

    The population-level signal

    Two Danish registry studies, built on men sanctioned for doping in fitness centers, give a view no clinic cohort can. In the first, 545 users matched to 5,450 controls, mortality was three times higher among users (HR 3.0, 95% CI 1.3 to 7.0), and acne, gynecomastia and erectile dysfunction each affected more than 10% of users. [Horwitz et al., J Intern Med 2019] The larger follow-up tracked 1,189 sanctioned men, mean age 27.4, against 59,450 controls over a mean of 11 years: 2.8% of users died versus 1% of controls, a hazard ratio of about 2.8, with hazard ratios of 3.6 for unnatural deaths and 2.2 for natural ones. [Windfeld-Mathiasen et al., JAMA 2024]

    Read these honestly. These are observational cohorts of men sanctioned for doping, not of patients in supervised clinics. Confounding is substantial: risk-taking behavior, polypharmacy and other substance use plausibly drive a large share of the unnatural-death excess, and the authors say so. These studies cannot tell you the mortality risk of supervised supraphysiologic dosing. What they establish is that the population using these doses dies earlier, and that the gap is not small.

    The part nobody puts in the advertisement

    Everything above is a physical risk, and physical risks can be weighed. This one is different, because it changes who is doing the weighing.

    Androgens produce a dependence syndrome. Reviewing seven studies, Kanayama, Brower, Wood, Hudson and Pope concluded that about 30% of illicit AAS users develop dependence, defined as continued use despite adverse effects on physical, psychosocial or occupational functioning. [Kanayama et al., Addiction 2009] An online survey of men active on bodybuilding and steroid forums found 23.4% of 479 users meeting dependence criteria. [de Zeeuw et al., Eur Addict Res 2023]

    The mechanism is worth understanding, because it is not the one people expect. Androgens are not acutely intoxicating; nobody is chasing a high. The trap is built from the withdrawal state instead. Stopping leaves a man hypogonadal for weeks to months while his own axis recovers, and that state produces fatigue, low libido and genuine depressive symptoms. As the same group put it, men experiencing prolonged dysphoric effects or frank major depression from that withdrawal hypogonadism may desire to resume AAS, thus contributing to dependence. [Kanayama et al., Drug Alcohol Depend 2010]

    Why this matters more, not less, in a clinic setting. A classic cycle has a built-in end date. A prescription renews. The commercial model that sells continuous “optimization” removes the natural off-ramp, and it does so for a drug where roughly a third of users struggle to stop, where stopping feels terrible, and where the person you would turn to for an honest assessment of whether you still need it is also the person billing you monthly for it. I am not alleging bad faith across an industry. I am pointing out an incentive structure that would concern us immediately in any other area of medicine.

    If you want the plain test of whether this applies to you, it is not how much you take. It is how you feel about stopping. A man who can say “I would come off tomorrow if the labs said to” is in a different position from one who has already decided that is not on the table.

    What TRAVERSE does and does not say

    TRAVERSE is the trial that gets cited at me most often, usually incorrectly. It enrolled 5,198 men aged 45 to 80 with symptoms and two fasting testosterone levels below 300 ng/dL, all with existing or high risk of cardiovascular disease, and randomized them to transdermal testosterone titrated to 350 to 750 ng/dL or placebo. Major adverse cardiac events occurred in 7.0% of the testosterone group versus 7.3% on placebo (HR 0.96, 95% CI 0.78 to 1.17), meeting noninferiority. [Lincoff et al., NEJM 2023]

    That is a genuinely important and reassuring result, and I use it to counsel patients who need treatment. But notice the three constraints built into it: diagnosed deficiency, a target inside the normal range, and a 33-month horizon. None of them describe sports TRT.

    And even inside those constraints, the trial was not uniformly clean. Significantly more men on testosterone had atrial fibrillation (3.5% vs 2.4%, P=.02), acute kidney injury (2.3% vs 1.5%, P=.04), pulmonary embolism (0.9% vs 0.5%), and nonfatal arrhythmias warranting intervention (5.2% vs 3.3%, P=.001). The investigators wrote that these events were not expected. [Cleveland Clinic summary] The trial’s own lead authors cautioned that the findings “should not be used as a justification for widespread prescription of these products to large numbers of men.” [Cleveland Clinic newsroom, 2023]

    Using a replacement-dose trial to vouch for performance dosing is a category error. If anything, the arrhythmia and thromboembolic signals at physiologic targets argue for more caution above them, not less.

    The definition anti-doping bodies already use

    There is one arena where this line has been drawn precisely, with money and careers on it, and it is worth knowing where it sits. Under WADA’s therapeutic use exemption framework, a TUE for testosterone is granted only for organic primary or secondary hypogonadism, a structural or genetic cause. Functional hypogonadism does not qualify. As the guidance is summarized for masters athletes: “TUE should only be approved for hypogonadism that has an organic etiology. TUE should not be approved for androgen deficiency due to functional disorder.” Andropause is explicitly not an acceptable diagnosis.

    USADA’s physician worksheet is blunter still: low levels of an endogenous hormone “absent a defined organic etiology will not justify the granting of a TUE, even if within standard of care & prescribed by a physician.”

    Read that last clause again, because it is the entire argument of this article stated by someone else: even if prescribed by a physician. Anti-doping authorities worked out decades ago that a prescription does not change what a substance does. They had to, because the alternative was a system where anyone with a sympathetic clinic could compete on exogenous androgen and call it medicine.

    Why the clinic model is the thing to look at

    It would be convenient to frame this as rogue operators versus real medicine. The more useful question is what the business model rewards, because that predicts the clinical behavior better than anyone’s intentions do.

    Consider that the FDA’s own review of testosterone prescribing, the review that ultimately led it to mandate the TRAVERSE trial, found that “many men are treated with testosterone products even though their testosterone blood levels have never been checked.” That is the baseline problem in this field, and it predates the current wave of telehealth.

    Now add a subscription structure. In a model where revenue depends on continuing therapy, four things tend to follow, and you can check any clinic against them:

    • The diagnostic threshold drifts upward. If 300 ng/dL disqualifies most prospective patients”optimal” ranges that start at 600 or 800 solve a business problem elegantly. Watch for any clinic whose stated target range has no source.
    • Symptoms do the diagnostic work. Fatigue, low mood, poor sleep and reduced libido are real, common, and caused by many things. A questionnaire that routes nearly everyone toward treatment is a sales funnel wearing a lab coat.
    • Reversible causes go unexamined. Treating the sleep apnea, the obesity, the alcohol intake or the untreated depression produces a patient who does not need a monthly prescription. That is a clinical success and a revenue loss.
    • Deprescribing never comes up. In legitimate practice”let’s see whether you still need this” is a routine sentence. Ask when you last heard it.

    If you are evaluating a clinic, five questions will tell you most of what you need to know. What was my pre-treatment level, measured twice, in the morning? What is the target range you are treating me to, and whose guideline is that from? Did you check LH, FSH, SHBG and prolactin to find out why my level is low? What is your plan if my hematocrit reaches 54%? And if I want children in five years, what changes today?

    A clinic practicing real medicine answers all five without friction. I would not stay at one that cannot.

    The strongest case, both ways

    The strongest case for the clinics

    • Men are going to use these drugs regardless. Supervision with real labs and pharmaceutical product is safer than an underground vial and a forum protocol.
    • The 300 ng/dL cutoff was derived largely from trials in men over 45 and fits a symptomatic 35-year-old poorly. A level of 320 is not automatically fine.
    • Continuous steady dosing avoids the post-cycle crash, which is when much of the psychiatric and cardiovascular turbulence of classic cycling appears.
    • Medicine has always treated conditions that sit on a spectrum rather than a cutoff, and the line at 300 is a convention, not a biological cliff.

    Where that case breaks

    • Harm reduction describes supervizing a risk. It does not license marketing the result as a health intervention, which is what is happening.
    • The cutoff debate is an argument for better diagnosis, not for targeting 1,200 ng/dL. Nobody resolves a flawed threshold by tripling the target.
    • Continuous dosing means greater cumulative lifetime exposure, which is the variable Baggish found tracked with coronary plaque.
    • Roughly a quarter of former users had not recovered their own production years later. Started at 30, that is a four-decade prescription.
    • Roughly 30% develop dependence. A model with no end date and a monthly bill is poorly designed to catch that.

    I hold both of these at once, and I think any honest clinician does. A man determined to use these compounds is better off with real labs, sterile product and a physician watching his hematocrit than with a forum protocol and a vial from a stranger. What I object to is not supervision. It is supervision marketed as optimization, which turns a risk being managed into a benefit being sold.

    What I tell patients

    I do not open with a lecture, because the man in front of me usually already knows what he is asking for. I work through four things.

    First, get the diagnosis right. Two early-morning draws, fasting, on separate days, plus LH, FSH, SHBG, prolactin and a hematocrit. Free testosterone when SHBG is abnormal. A single afternoon total testosterone from a direct-to-consumer panel is not a diagnosis.

    Second, treat the things that lower testosterone. Roughly half of men with obesity have reduced levels, [Cleveland Clinic J Med, 2024] and sleep apnea, alcohol, opioids, overtraining and untreated depression all pull the number down. Several of my patients who arrived asking for testosterone did not need it six months later.

    Third, if you are deficient, treat properly. Lowest dose that reaches mid-normal, hematocrit and PSA on schedule, fertility discussed and hCG or a SERM considered before starting if children are a possibility, not after.

    Fourth, if you want performance doses, I will tell you what they are. I am not going to pretend a 200 mg weekly protocol aimed at 1,100 ng/dL in a man with a baseline of 520 is replacement therapy. I will tell him it is a cycle, that it will likely suppress his fertility, that his hematocrit will climb, that a quarter of men in his position do not recover their own production, and that the cardiac data on long-term users is genuinely concerning. Then it is his decision, made with accurate information. That is a different conversation than the one he gets from an ad.

    Bottom line

    Testosterone replacement therapy is one of the more satisfying treatments in medicine when it is used for what it is for. A man with real deficiency, treated to a normal level and monitored properly, often gets his life back. I have watched it happen many times, and the TRAVERSE data should make physicians less skittish about providing it.

    “Sports TRT” is a different product wearing that product’s clothes. The dose is above replacement, the indication is appearance and performance, and the clinical category it belongs to is supraphysiologic androgen use. You are allowed to make that choice as an adult. What you are not entitled to is the belief that a prescription repeals the dose-response curve.

    References

    1. Mulhall JP, et al. Evaluation and Management of Testosterone Deficiency: AUA Guideline. J Urol. 2018;200(2):423-432. PubMed 29601923
    2. Bhasin S, et al. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PubMed 29562364
    3. Bhasin S, et al. Testosterone dose-response relationships in healthy young men. Am J Physiol Endocrinol Metab. 2001;281(6):E1172-E1181. PubMed 11701431
    4. Bhasin S, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab. 2005;90(2):678-688. PubMed 15562020
    5. Coviello AD, et al. Effects of graded doses of testosterone on erythropoiesis in healthy young and older men. J Clin Endocrinol Metab. 2008;93(3):914-919. PubMed 18160461
    6. World Health Organization Task Force on Methods for the Regulation of Male Fertility. Contraceptive efficacy of testosterone-induced azoospermia in normal men. Lancet. 1990;336(8721):955-959. PubMed 1977002
    7. World Health Organization Task Force. Contraceptive efficacy of testosterone-induced azoospermia and oligozoospermia in normal men. Fertil Steril. 1996;65(4):821-829. PubMed 8654646
    8. World Health Organization Task Force. Effects of testosterone enanthate in normal men: experience from a multicenter contraceptive efficacy study. Fertil Steril. 1996;65(3):626-636. PubMed 8774299
    9. Baggish AL, et al. Cardiovascular Toxicity of Illicit Anabolic-Androgenic Steroid Use. Circulation. 2017;135(21):1991-2002. PubMed 28533317 · PMC5614517
    10. Rasmussen JJ, et al. Former Abusers of Anabolic Androgenic Steroids Exhibit Decreased Testosterone Levels and Hypogonadal Symptoms Years after Cessation. PLoS One. 2016;11(8):e0161208. PMC4988681
    11. Horwitz H, Andersen JT, Dalhoff KP. Health consequences of androgenic anabolic steroid use. J Intern Med. 2019;285(3):333-340. PubMed 30460728
    12. Windfeld-Mathiasen J, et al. Mortality Among Users of Anabolic Steroids. JAMA. 2024;331(14):1229-1230. JAMA
    13. Windfeld-Mathiasen J, et al. Cardiovascular Disease in Anabolic Androgenic Steroid Users. Circulation. 2025. doi:10.1161/CIRCULATIONAHA.124.071117. Record and abstract
    14. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG Jr. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction. 2009;104(12):1966-1978. PMC2780436
    15. Kanayama G, Brower KJ, Wood RI, Hudson JI, Pope HG Jr. Treatment of anabolic-androgenic steroid dependence: emerging evidence and its implications. Drug Alcohol Depend. 2010;109(1-3):6-13. PMC2875348
    16. de Zeeuw TI, Brunt TM, van Amsterdam J, et al. Anabolic Androgenic Steroid Use Patterns and Steroid Use Disorders in a Sample of Male Gym Visitors. Eur Addict Res. 2023;29(2):99-108. Karger
    17. Pope HG Jr, et al. Adverse Health Consequences of Performance-Enhancing Drugs: An Endocrine Society Scientific Statement. Endocr Rev. 2014;35(3):341-375. PubMed 24423981
    18. Lincoff AM, et al. Cardiovascular Safety of Testosterone-Replacement Therapy (TRAVERSE). N Engl J Med. 2023;389(2):107-117. NEJM · PubMed 37326322
    19. Testosterone deficiency diagnosis and thresholds. Cleve Clin J Med. 2024;91(2):93-95. CCJM
    20. WADA TUE Physician Guidelines, Male Hypogonadism; USADA Testosterone TUE Physician Worksheet. USADA worksheet · WMA summary of WADA TUEC guidelines

    Educational content only. This article is not medical advice for any individual and does not establish a physician-patient relationship. Do not start, stop or change testosterone therapy without consulting your own physician. If you are currently on a supraphysiologic protocol, stopping abruptly carries its own risks and should be managed clinically.